ERBB2 and central nervous system cancer: Although toxicity remains a concern, our results have led to the inclusion of neratinib and capecitabine as a recommended treatment option for HER2-positive CNS disease in the National Comprehensive Cancer Network’s CNS Cancers guidelines.28 We await the data from the NALA study to inform our understanding of the relative merits of neratinib- versus lapatinib-based regimens for the treatment of patients with progressive extracranial disease.